Related Experiment Video
Updated: Dec 14, 2025
10:30
High-resolution Confocal Imaging of the Blood-brain Barrier: Imaging, 3D Reconstruction, and Quantification of Transcytosis
Published on: November 16, 2017
12.2K
Abstract:
Blueprint Medicines entered into a strategic partnership with Roche to jointly develop and commercialize pralsetinib, a targeted agent for RET-driven malignancies. If pralsetinib is approved, Roche's vast commercial network and diagnostic abilities could help the drug compete against another RET inhibitor, Eli Lilly's selpercatinib, which was approved in May.
